Acute Pain - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 96

Acute Pain - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acute Pain - Pipeline Review, H2 2011', provides an overview of the Acute Pain therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. 'Acute Pain - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Pain.
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Acute Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Pain
Acute Pain Therapeutics under Development by Companies
Acute Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acute Pain Therapeutics - Products under Development by Companies
Acute Pain Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Pain Therapeutics Development
Johnson & Johnson
Merck & Co., Inc.
BioLineRx, Ltd.
Pacira Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Anavex Life Sciences Corp.
NeurogesX, Inc.
Nuvo Research Inc.
CombinatoRx, Incorporated
Cerimon Pharmaceuticals, Inc.
Sanochemia Pharmazeutika AG
Intas Pharmaceuticals Ltd.
Transdel Pharmaceuticals, Inc.
Grunenthal GmbH
Rottapharm SpA
Xenome Ltd.
Iroko Pharmaceuticals, LLC
Xanodyne Pharmaceuticals, Inc.
KemPharm, Inc.
Troikaa Pharmaceuticals Ltd.
RaQualia Pharma Inc.
Acute Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Oxecta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketotransdel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR 4056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arcoxia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nucynta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-1576 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-9674 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-5752 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-6052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XP21B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eptifibatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xen2174 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Type Calcium Channels Blockers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorbitol + Phenylephrine + Morphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1519 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxycodone Immediate Release - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufentanil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Remifentanil + Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac Sodium Matrix Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topical Diclofenac Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IN-PHARM-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-9998 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Papaverine Hydrochloride + Diclofenac Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IP 940 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IP 880 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Z212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DepoNSAID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRI-ANA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-7EAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Pain Therapeutics – Drug Profile Updates
Acute Pain Therapeutics - Discontinued Products
Acute Pain - Featured News
Jul 01, 2011: Acura Pharmaceuticals Receives $20m Milestone Payment From Pfizer For OXECTA
Jun 20, 2011: Pfizer And Acura Announce FDA Approval Of Oxectatm CII
May 31, 2011: AcelRx Receives $5.6m Grant From Department Of Defense To Develop ARX-04
Mar 28, 2011: QRxPharma On Track To File New Drug Application For MoxDuo IR
Jul 16, 2010: Start Of Phase III Clinical Trial For MRX-7EAT In Patients With Acute Pain
May 26, 2009: Etodolac Patch (MRX-7EAT) Became Available For Phase I Clinical Trial In U.S.
Apr 23, 2009: Issuance Of US patent 7,507,717 Entitled “Type II Chi-conotoxin Peptides (Noradrenaline Transporter Inhibitors)” To Xen2174
Nov 17, 2008: APR And Fidia Have Received IND Approval From FDA For A New NSAID Matrix Patch Product
Sep 25, 2008: Xenome Initiates Phase II Clinical Trial Of Xen2174 In Acute Pain
Sep 11, 2008: Cerimon Pharmaceuticals Announces Positive Results From A Phase II Clinical Study Of Its Diclofenac Sodium Patch For Acute Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Pain, H2 2011
Products under Development for Acute Pain – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, H2 2011
Merck & Co., Inc., H2 2011
BioLineRx, Ltd., H2 2011
Pacira Pharmaceuticals, Inc., H2 2011
AcelRx Pharmaceuticals, Inc., H2 2011
Pfizer Inc., H2 2011
Sun Pharmaceutical Industries Limited, H2 2011
Anavex Life Sciences Corp., H2 2011
NeurogesX, Inc., H2 2011
Nuvo Research Inc., H2 2011
CombinatoRx, Incorporated, H2 2011
Cerimon Pharmaceuticals, Inc., H2 2011
Sanochemia Pharmazeutika AG, H2 2011
Intas Pharmaceuticals Ltd., H2 2011
Transdel Pharmaceuticals, Inc., H2 2011
Grunenthal GmbH, H2 2011
Rottapharm SpA, H2 2011
Xenome Ltd., H2 2011
Iroko Pharmaceuticals, LLC, H2 2011
Xanodyne Pharmaceuticals, Inc., H2 2011
KemPharm, Inc., H2 2011
Troikaa Pharmaceuticals Ltd., H2 2011
RaQualia Pharma Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Acute Pain Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Acute Pain, H2 2011
Products under Development for Acute Pain – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Acute Coronary Syndrome - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Inflammatory Pain - Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2012
• Acute Heart Failure - Pipeline Review, H2 2012
• Osteoarthritis Pain - Pipeline Review, H2 2012
• Lung Injury - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012